BackSAB Biotherapeutics Overview

SAB Biotherapeutics Common Stock

SAB Biotherapeutics's common stock is $9K.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$9000.00
↑ 89.23% YoYΔ $4244.00 vs prior year quarter

Peer trimmed avg / median

Loading

SAB Biotherapeutics Common Stock History

Loading

SAB Biotherapeutics vs. peers: Common Stock Comparison

Loading

SAB Biotherapeutics Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

SAB Biotherapeutics (SABS) FAQ

The latest common stock for SABS is $9K as of September 2026. That compares with $4.8K in the prior-year period — up 89.2% year over year. Investors often review this figure alongside SAB Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, SABS's common stock moved from $4.8K to $9K — a 89.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in SAB Biotherapeutics's operating scale or balance-sheet position.

A common stock figure of $9K for SABS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SABS's common stock ($9K), review year-over-year change from $4.8K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.